Nebenwirkungen · Lumigan
LUMIGAN 0.3 mg/ml eye drops, solution, in single-dose container · Abschnitt 4.8 · PDF-Seite 24
HOS-109780 · Präparat HOS-093245
In clinical studies, over 1 800 patients have been treated with LUMIGAN 0.3 mg/ml (multi-dose formulation). On combining the data from phase III monotherapy and adjunctive LUMIGAN 0.3 mg/ml (multi-dose formulation) usage, the most frequently reported adverse reactions were: • growth of eyelashes in up to 45% in the first year with the incidence of new reports decreasing to 7% at 2 years and 2% at 3 years • conjunctival hyperaemia (mostly trace to mild and thought to be of a non-inflammatory nature) in up to 44% in the first year with the incidence of new reports decreasing to 13% at 2 years and 12% at 3 years • ocular pruritus in up to 14% of patients in the first year with the incidence of new reports decreasing to 3% at 2 years and 0% at 3 years.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-11-18T14:06:00Z · SHA-256 53709aeb7ae4918b6258ed233ae9c0bd61e40c01b7fc2e14ae82d0a3c8327635 · Passage 8ec4cf325f9372c5bf24fcb6d7b3ffadb22ffc4098f863e0936b0cbf0051b9d0 · Zeichen 5628–6429 im Abschnitt